GlassScriptPhysician profile
Katie N Mann
NPI 1780198655
$8,314.04
in general payments reported to CMS, 2019-2025
28 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $621 · 2022: $1,325 · 2023: $2,223 · 2024: $2,118 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,217 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,217.42 |
| Education | $150.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,252.69 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $887.80 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $871.13 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $834.16 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $771.63 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $681.66 | 2021-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $467.25 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Alkermes, INC. | $388.39 | 2021-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $352.95 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $306.22 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $264.95 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $197.96 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $154.75 | 2021-2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $152.84 | 2022-2024 | Spravato |
| Corium, LLC | $119.80 | 2022-2023 | Azstarys |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $110.86 | 2021 | |
| Tempus Ai, INC | $97.09 | 2024 | |
| Ironshore Pharmaceuticals INC. | $81.94 | 2022-2024 | Jornay Pm |
| Bausch Health US, LLC | $49.74 | 2023-2025 | Wellbutrin, Aplenzin |
| Supernus Pharmaceuticals, INC. | $42.35 | 2023 | Qelbree |
| Avadel Cns Pharmaceuticals, LLC | $39.39 | 2025 | Lumryz |
| Sunovion Pharmaceuticals INC. | $39.38 | 2021 | |
| Idorsia Pharmaceuticals US INC | $34.50 | 2022-2023 | Quviviq |
| Neos Therapeutics, LP | $31.85 | 2024-2025 | Adzenys Xr-Odt |
| Tris Pharma INC | $28.51 | 2023 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $23.56 | 2025 | Jornay Pm |
| Tms Neurohealth Centers INC. | $15.49 | 2025 | Tms Neurohealth Centers INC. |
| Noven Therapeutics, LLC | $15.20 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.